Key Drivers
- Cash Flow Strength
- Thin Margins
- Intangible Risk
AIAI Summary
Takeda looks more like a credible transition story than a slow legacy pharma name now, with ORZEYFUL, zasocitinib, and pediatric IV ENTYVIO offering near-term upside backed by strong cash flow, but the investment still hinges on proving these launches can outrun Vyvanse erosion, litigation, and margin pressure before the stock can re-rate.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Flow Strength
- •Thin Margins
- •Intangible Risk
Takeda looks financially resilient on cash flow and liquidity, but weak returns, heavy intangibles, and a rich multiple limit upside.
Price Behavior
Key Price Behavior Insights:
- •Higher-lows setup
- •Tight consolidation
- •Breakout needed
TAK has a constructive but range-bound setup over the last month, holding above $17 with higher lows and a rebound from $16.56, but it still needs a decisive break above $17.75 to confirm further upside and avoid a pullback toward $17.02/$16.56.
Brief dip to $16.56 followed by a quick recovery above $17.00
Sentiment & News
Key News Insights:
- •FDA approval
- •India expansion
- •Generic erosion
Takeda is gaining regulatory and pipeline momentum with FDA approval of ORZEYFUL, QDENGA's India launch, and encouraging zasocitinib data, but near-term upside is tempered by generic erosion and uncertainty around a major Entyvio successor.
The news is constructive for Takeda's long-term growth story, but ongoing mature-product pressure may cap near-term share gains
Similar Companies in Healthcare
Other companies in the same sector with AI ratings